Dynavax Technologies (NASDAQ:DVAX) Upgraded by BidaskClub to Hold

Share on StockTwits

BidaskClub upgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a sell rating to a hold rating in a research report sent to investors on Thursday, BidAskClub reports.

Other research analysts have also recently issued reports about the company. ValuEngine raised Dynavax Technologies from a sell rating to a hold rating in a research report on Thursday, August 1st. Cowen reiterated a buy rating on shares of Dynavax Technologies in a research note on Monday, June 3rd. Cantor Fitzgerald upgraded Dynavax Technologies from a neutral rating to an overweight rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. Zacks Investment Research upgraded Dynavax Technologies from a hold rating to a buy rating and set a $4.50 price objective for the company in a research note on Friday, August 16th. Finally, William Blair reiterated a buy rating on shares of Dynavax Technologies in a research note on Friday, August 16th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Dynavax Technologies currently has an average rating of Buy and a consensus target price of $16.88.

Shares of DVAX stock opened at $4.32 on Thursday. The stock has a market cap of $289.94 million, a P/E ratio of -1.69 and a beta of 0.63. Dynavax Technologies has a one year low of $2.60 and a one year high of $14.35. The stock has a fifty day moving average price of $3.51 and a 200 day moving average price of $6.13. The company has a debt-to-equity ratio of 19.95, a current ratio of 4.30 and a quick ratio of 3.47.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.03). The firm had revenue of $8.30 million during the quarter, compared to the consensus estimate of $8.24 million. Dynavax Technologies had a negative return on equity of 304.71% and a negative net margin of 781.10%. The firm’s revenue for the quarter was up 564.0% compared to the same quarter last year. During the same period last year, the business earned ($0.63) earnings per share. Equities research analysts anticipate that Dynavax Technologies will post -1.99 EPS for the current year.

In other Dynavax Technologies news, SVP Robert Coffman sold 32,218 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $4.58, for a total transaction of $147,558.44. Following the completion of the transaction, the senior vice president now directly owns 132,470 shares in the company, valued at $606,712.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Francis Cano acquired 16,667 shares of the company’s stock in a transaction on Monday, August 12th. The shares were bought at an average price of $3.00 per share, with a total value of $50,001.00. Following the completion of the purchase, the director now directly owns 118,484 shares of the company’s stock, valued at $355,452. The disclosure for this purchase can be found here. Corporate insiders own 4.90% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Ladenburg Thalmann Financial Services Inc. raised its stake in Dynavax Technologies by 95.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 3,402 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Dynavax Technologies by 148.4% in the second quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 4,445 shares in the last quarter. Wedbush Securities Inc. acquired a new stake in shares of Dynavax Technologies in the second quarter valued at $42,000. M&T Bank Corp increased its stake in shares of Dynavax Technologies by 29.5% in the second quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 3,116 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Dynavax Technologies in the second quarter valued at $59,000. Hedge funds and other institutional investors own 82.41% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.